Efek Polimorfisme Terhadap Kerentanan dan Tatalaksana Tuberkulosis Paru

Article Sidebar

PDF
Published: Nov 28, 2024
DOI: https://doi.org/10.37715/pmj.v5i2.4776

Main Article Content

M. Rusdi
Program Studi S2 Ilmu Biomedik, Fakultas Kedokteran, Universitas Sriwijaya, Palembang, Sumatera Selatan, Indonesia
Syarinta Adenina
Departemen Farmakologi, Fakultas Kedokteran, Universitas Sriwijaya, Palembang, Sumatera Selatan, Indonesia

Abstract

Pulmonary tuberculosis (TB) remains the second leading cause of death from a single infectious agent. The number of people with pulmonary TB in the world still increased, and TB treatment success percentage in Indonesia has not reached the target until now. Genetic polymorphisms are defined as DNA variations seen in ≥1% of the population. The study of genetic polymorphisms can help identify disease risk, predict drug efficacy and safety, and determine the right chemotherapeutic agent with a dose that suits each patient. Various genetic polymorphisms associated with pulmonary TB susceptibility have been found, including polymorphisms of the NRAMP1, HLA-DRB1, vitamin D receptor, TNF-α, and IFN-γ genes. In addition, several genetic polymorphisms associated with TB treatment were also found, such as SLCO1B1, NAT2, SLC2A9, and ABCB1 genes. Detection of genetic polymorphisms in each individual can help predicts TB risk and improve TB treatment success and reduce side effects that may occur due to TB treatment.

Article Details

How to Cite
Rusdi, M., & Adenina, S. (2024). Efek Polimorfisme Terhadap Kerentanan dan Tatalaksana Tuberkulosis Paru. Prominentia Medical Journal, 5(2), 61–71. https://doi.org/10.37715/pmj.v5i2.4776
Issue
Vol. 5 No. 2 (2024): Prominentia Medical Journal
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

References

Alzayer, Z. and Al Nasser, Y. (2021) ‘Primary Lung Tuberculosis’, StatPearls, pp. 1–10. Available at: http://www.ncbi.nlm.nih.gov/pubmed/33620814.

Areeshi, M. Y. et al. (2021) ‘IFN-γ +874 A>T (rs2430561) gene polymorphism and risk of pulmonary tuberculosis: A meta-analysis’, Archives of Medical Science, 17(1), pp. 177–188. doi: 10.5114/aoms.2019.88481.

Barberis, I. et al. (2017) ‘The history of tuberculosis: From the first historical records to the isolation of Koch’s bacillus’, Journal of Preventive Medicine and Hygiene, 58(1), pp. E9–E12.

Charles, A. et al. (2021) ‘Influence of TLR-8 Gene Polymorphisms ( rs3764880 and rs3788935 ) Associated to Pulmonary Tuberculosis in Kupang , Indonesia Tuberculosis still becomes a leading cause prevalent in this area . Since the genetic background of people in East Nusa Tenggara (’, 9(1), pp. 9–15.

Chigutsa, E. et al. (2011) ‘The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: Dosing implications’, Antimicrobial Agents and Chemotherapy, 55(9), pp. 4122–4127. doi: 10.1128/AAC.01833-10.

Dai, Y. et al. (2023) ‘SLC2A9 Gene Polymorphism Is Associated with Elevated Serum Uric Acid Caused by Pyrazinamide’, Journal of Clinical Pharmacy and Therapeutics, 2023. doi: 10.1155/2023/6677236.

Gao, L. et al. (2010) ‘Vitamin D receptor genetic polymorphisms and tuberculosis: updated systematic review and meta-analysis.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 14(1), pp. 15–23.

Ghermi, M. et al. (2021) ‘Interferon-γ (+874 T/A) and interleukin-10 (−1082 G/A) genes polymorphisms are associated with active tuberculosis in the Algerian population of Oran’s city’, Indian Journal of Tuberculosis, 68(2), pp. 221–229. doi: 10.1016/j.ijtb.2020.08.015.

Gummadi, A. C. and Guddati, A. K. (2021) ‘Genetic Polymorphisms in Pharmaceuticals and Chemotherapy’, World Journal of Oncology, 12(5), pp. 149–154. doi: 10.14740/wjon1405.

Hemanth Kumar, A. et al. (2017) ‘N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis’, Indian Journal of Medical Research, 145(1), p. 118. doi: 10.4103/ijmr.IJMR_2013_15.

Iannuzzi, M. C., Maliarik, M. and Rybicki, B. (2002) ‘Genetic polymorphisms in lung disease: Bandwagon or breakthrough?’, Respiratory Research, 3. doi: 10.1186/rr164.

Kementrian Kesehatan RI (2020) Pedoman Nasional Pelayanan Kedokteran Tatalaksana Tuberkulosis. Jakarta.

Lee, Y. H. and Song, G. G. (2015) ‘Vitamin D receptor gene FokI, TaqI, BsmI, and ApaI polymorphisms and susceptibility to pulmonary tuberculosis: A meta-analysis’, Genetics and Molecular Research, 14(3), pp. 9118–9129. doi: 10.4238/2015.August.7.21.

Odera, S. et al. (2022) ‘Association between human leukocyte antigen class II (HLA-DRB and-DQB) alleles and outcome of exposure to Mycobacterium tuberculosis: a cross-sectional study in Nairobi, Kenya’, Pan African Medical Journal, 41. doi: 10.11604/pamj.2022.41.149.30056.

Oshiro, C. et al. (2010) ‘PharmGKB very important pharmacogene: SLCO1B1’, Pharmacogenetics and Genomics, 20(3), pp. 211–216. doi: 10.1097/FPC.0b013e328333b99c.

Pakasi, T. A. et al. (2012) ‘Distribution of D543N NRAMP1 polymorphism in tuberculosis patients from Kupang, east region of Indonesia’, Medical Journal of Indonesia, 21(3), pp. 160–165. doi: 10.13181/mji.v21i3.501.

Pontual, Y. et al. (2017) ‘ABCB1 gene polymorphism associated with clinical factors can predict drug-resistant tuberculosis’, Clinical Science, 131(15), pp. 1831–1840. doi: 10.1042/CS20170277.

Rashedi, J. et al. (2014) ‘Vitamin D receptor gene polymorphism and vitamin D plasma concentration: Correlation with susceptibility to tuberculosis’, Advanced Pharmaceutical Bulletin, 4(Suppl 2), pp. 607–611. doi: 10.5681/apb.2014.089.

Santoso, P. et al. (2022) ‘Polymorphisms of SLCO1B1 Gene in Sundanese Ethnic Population of Tuberculosis Patients in Indonesia’, Acta Medica Indonesiana, 54(4), pp. 517–523.

Sinaga, B. Y. M. and Amir, Z. (2021) ‘Tumor necrosis factor-alpha-308g/a polymorphism associated with increased risk for pulmonary tuberculosis in Medan City, Indonesia’, Open Access Macedonian Journal of Medical Sciences, 9(A), pp. 7–11. doi: 10.3889/oamjms.2021.5559.

Sun, Y. ping et al. (2019) ‘Association between SLC2A9 Genetic Variants and Risk of Hyperuricemia in a Uygur Population’, Current Medical Science, 39(2), pp. 243–249. doi: 10.1007/s11596-019-2026-2.

Tong, X. et al. (2015) ‘Polymorphisms in HLA-DRB1 Gene and the Risk of Tuberculosis: A Meta-analysis of 31 Studies’, Lung, 193(2), pp. 309–318. doi: 10.1007/s00408-015-9692-z.

WHO (2022) Global Tuberculosis Report. Geneva.

World Health Organization, (WHO) (2022) WHO consolidated guidelines on tuberculosis., WHO Press.

Wu, S. et al. (2019) ‘Polymorphisms of cytokine genes and tuberculosis in two independent studies’, Scientific Reports, 9(1), pp. 1–11. doi: 10.1038/s41598-019-39249-4.

Yuan, L. et al. (2017) ‘NRAMP1 D543N and INT4 polymorphisms in susceptibility to pulmonary tuberculosis: A meta-analysis’, Infection, Genetics and Evolution, 54, pp. 91–97. doi: 10.1016/j.meegid.2017.06.022.

Yuliwulandari, R. et al. (2016) ‘NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis’, Journal of Human Genetics, 61(6), pp. 533–537. doi: 10.1038/jhg.2016.10.